SIGA Technologies

SIGA Technologies, Inc. is a commercial-stage pharmaceutical company, which engages in the development and commercialization of solutions for serious unmet medical needs and biothreats. The firm develops therapeutic solutions for lethal pathogens including smallpox, Ebola, dengue, Lassa fever, and other dangerous viruses. It offers an orally administered antiviral drug that targets orthopoxviruses under the TPOXX brand. The company was founded by Steven Oliveira on December 28, 1995 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

SIGA Technologies reports strong revenue diversification and growth opportunities

SIGA Technologies delivered robust financial results in 2022, showcasing revenue diversification and positive cash flows. With a focus on TPOXX and upcoming FDA submissions, the company is poised for growth. Challenges lie in regulatory hurdles and operational complexities, but opportunities abound in US Government procurement and international sales expansion.

SIGA Technologies projects robust 2023 performance with strategic growth initiatives

SIGA Technologies is poised for a successful 2023, driven by strong financial expectations and product delivery targets. The company's focus on innovation, strategic partnerships, and market expansion positions it well for future growth. Challenges in negotiations, clinical trials, and program scalability require careful management to capitalize on emerging opportunities.

SIGA Technologies projects robust growth in 2023 amidst operational challenges

SIGA Technologies is poised for strong financial performance in the second half of 2023, with revenue expectations and operating income growth.
The company's focus on TPOXX as a key treatment for orthopoxviruses and international sales growth positions it well for future success.
While facing challenges in trial data analysis and CEO transition, SIGA has opportunities for market expansion and revenue diversification.

SIGA Technologies reports solid Q3 earnings amidst packaging challenges

SIGA Technologies is navigating packaging delays and inventory build-up while maintaining a strong financial position. Promising programs and trials indicate growth potential, with opportunities for additional orders and upsells in the EU market.

SIGA Technologies excels in Q4 2023 earnings, eyes innovation and growth

SIGA Technologies delivered impressive financial results in Q4 2023, with strong revenue growth and profitability. Despite facing challenges in contract extensions and manufacturing capacity, the company remains focused on innovation and expansion to drive future growth and value creation.

SIGA Technologies excels in Q1 2024, navigates health challenges

SIGA Technologies delivered a strong performance in Q1 2024, marked by revenue growth, operational efficiency, and strategic advancements. While maintaining a solid financial position, the company faces challenges related to public health concerns and regulatory complexities. Leveraging opportunities in product expansion and global partnerships will be key to sustaining growth and market leadership.

SIGA Technologies reports robust Q2 earnings and global expansion plans

SIGA Technologies' Q2 2024 performance reflects strong revenue growth and financial stability.
The company's focus on diversification, international expansion, and innovation positions it for future success.
Challenges in government contract negotiations and regulatory approvals are balanced by growth opportunities and positive outlook.

SIGA Technologies reports robust Q3 earnings and eyes global expansion

SIGA Technologies' Q3 2024 earnings call reflects strong financial performance, strategic partnerships, and a focus on innovation and market expansion.
The company's commitment to product safety, efficacy, and diverse revenue sources positions it well for future growth and sustained profitability.
While facing challenges in regulatory approvals and market competition, SIGA's financial stability, product credibility, and growth opportunities present a positive outlook.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW YORK, Sept. 07, 2021 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that Dr. Phil Gomez, the Company's Chief Executive Officer, will be a speaker at the NCT USA conference on September 8, in Baltimore, Maryland.

SIGA Technologies CEO to Speak at NCT USA Conference September 8, 2021

SIGA Technologies, Inc. (SIGA) CEO Phil Gomez Q2 2021 Results - Earnings Call Transcript

- Approximately $7 Million in International Sales of Oral TPOXX® in the Second Quarter –

SIGA Reports Financial Results for Three and Six Months Ended June 30, 2021

NEW YORK, July 29, 2021 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Thursday, August 5th, 2021. Participating on the call will be Dr. Phil Gomez, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer.

SIGA Technologies to Host Business Update Call on August 5th, 2021 Following Release of Second Quarter 2021 Financial Results

NEW YORK, July 29, 2021 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that it has entered into a collaboration with Oxford University in the United Kingdom (UK) to provide TPOXX® (tecovirimat) under an expanded access protocol to treat individuals affected by monkeypox in the Central African Republic (CAR). Under the agreement, Oxford University will sponsor the protocol and study in CAR, and SIGA will provide up to 500 courses of TPOXX (tecovirimat) at no cost.

SIGA Announces Collaboration with Oxford University to Support Expanded Access Protocol for Use of TPOXX® (Tecovirimat) To Treat Monkeypox in Central African Republic

NEW YORK, June 30, 2021 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that it provided TPOXX® (tecovirimat) to Liverpool University Hospitals NHS Foundation Trust, in the United Kingdom (UK). TPOXX, which is approved in the United States for the treatment of smallpox, was delivered to Liverpool for compassionate treatment for a patient confirmed to be infected with monkeypox.

SIGA Supplies TPOXX® (Tecovirimat) as Compassionate Treatment for Monkeypox Case in the United Kingdom

Biogen

Innoviva

SAGE Therapeutics

Searching for undervalued biotech stocks? Here are 4 biotech stocks to buy for a mix of value and growth in any portfolio.

4 Undervalued Biotech Stocks That Belong On Every Investor's Buy List

Agenus

Atossa Genetics

Avid Bioservices

Cocrystal Pharma

Ocugen, Inc.

Sio Gene Therapies

Small-cap stocks in the biotech space have been in a slump, but these seven companies could see big moves just around the corner. The post 7 Small-Cap Biotech Stocks to Watch for Upcoming Catalysts appeared first on InvestorPlace.

7 Small-Cap Biotech Stocks to Watch for Upcoming Catalysts

SIGA Technologies, Inc. (SIGA) CEO Phil Gomez on Q1 2021 Results - Earnings Call Transcript

- Important for Patients Who Cannot Swallow Oral Capsules - - Important for Patients Who Cannot Swallow Oral Capsules -

SIGA Announces New Drug Application Filing with FDA for Intravenous Formulation of TPOXX

SIGA Technologies, Inc. is a commercial-stage pharmaceutical company developing drugs for health security and infectious diseases globally with a market niche in smallpox servicing various government agencies. SIGA Technologies' pipeline consists of one core FDA-approved oral drug known as TPOXX (tecovirimat), a pipeline of 3 others based on TPOXX-administration-changed/smallpox sub-indications, and one other early-stage smallpox small-molecule formulation.

SIGA Technologies: Biodefense Pharma Unlocks New Value Abroad For TPOXX

NEW YORK, March 23, 2021 (GLOBE NEWSWIRE) -- Cipla Therapeutics, a division of Cipla USA Inc., an affiliate of Cipla Limited (BSE: 500087; NSE: CIPLA EQ; referred to as "Cipla") and SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market announced entering into a strategic partnership to deliver sustained innovation and access to novel antibacterial drugs, particularly against biothreats.

Cipla Therapeutics and SIGA Technologies Announce Strategic Partnership to support innovation and provide access to novel antibacterial drugs against biothreats

SIGA Technologies, Inc. (SIGA) CEO Phil Gomez on Q4 2020 Results - Earnings Call Transcript

-  Approximately 363,000 Courses of Oral TPOXX® Delivered to U.S. Government in 2020 –

SIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2020

NEW YORK, Feb. 26, 2021 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Thursday, March 4, 2021. Participating on the call will be Dr. Phil Gomez, Chief Executive Officer, Daniel Luckshire, Chief Financial Officer, and Dr. Dennis Hruby, Chief Scientific Officer.

SIGA Technologies to Host Business Update Call on March 4, 2021 Following Release of Year End 2020 Financial Results

Second Contract by a Canadian Governmental Agency for the Procurement of Oral TPOXX

SIGA Announces Public Health Agency of Canada Contract Award to Purchase Up To Approximately $33 Million of Oral TPOXX®

NEW YORK, Nov. 12, 2020 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Dr. Dennis Hruby, Chief Scientific Officer, will participate in a panel discussion at the Non-Conventional Threats (NCT) Asia Virtual Conference.

SIGA Technologies Chief Scientific Officer to Participate at NCT Asia Virtual Conference on November 13, 2020

SIGA Technologies, Inc. (SIGA) CEO Phillip Gomez on Q3 2020 Results - Earnings Call Transcript

- Third Quarter includes Delivery of Approximately 134,000 Courses of TPOXX® to U.S. Government –

SIGA Reports Financial Results for Three and Nine Months Ended September 30, 2020

NEW YORK, Oct. 29, 2020 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Thursday, November 5, 2020. Participating on the call will be Dr. Phil Gomez, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer.

SIGA Technologies to Host Business Update Call on November 5, 2020 Following Release of Third Quarter Financial Results

NEW YORK, Oct. 08, 2020 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that the Public Health Agency of Canada (PHAC) has issued an advanced contract award notice (ACAN), indicating that the PHAC intends to purchase up to 33,300 courses of oral TPOXX® (tecovirimat) within five years as specified in the ACAN, with 3,700 courses to be delivered by March 31, 2021; a cumulative total of 18,500 courses to be delivered by March 31, 2023; and an additional 14,800 courses to be delivered after March 31, 2023, subject to option exercise. The ACAN is required to remain open for at least 15 days, during which time a potential alternative supplier may submit a competing Statement of Capabilities. This ACAN follows, but is separate and incremental to, the issuance in April, 2020 of a contract by the Canadian Department of National Defence (CDND) for the delivery of up to 15,325 courses of oral TPOXX.

SIGA Announces Public Health Agency of Canada Intent to Purchase Up To 33,300 Courses of Oral TPOXX®

NEW YORK, Sept.  10, 2020  (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Dr. Phillip L. Gomez, SIGA’s Chief Executive Officer, will participate in a fireside chat at the Cantor Fitzgerald Virtual Global Healthcare Conference at 8:00 a.m. ET on Thursday, September 17, 2020.

SIGA to Participate at the Cantor Fitzgerald Virtual Global Healthcare Conference on September 17, 2020

NEW YORK, Aug.  31, 2020  (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Dr. Dennis Hruby, SIGA’s Chief Scientific Officer, has been named a recipient of the  2021 American Society for Microbiology (ASM) Award for Applied and Biotechnological Research . The award recognizes an outstanding scientist with distinguished research achievements in the development of products, processes and technologies that have advanced the microbial sciences.

Dr. Dennis Hruby Wins 2021 ASM Award for Applied and Biotechnological Research

SIGA Technologies' (SIGA) CEO Phil Gomez on Q2 2020 Results - Earnings Call Transcript

-  Second  Quarter includes Deliveries to SNS and First International Delivery -

News for SIGA Technologies Stock (SIGA)